Immuneering (NASDAQ:IMRX) Posts Earnings Results, Misses Estimates By $0.16 EPS

Immuneering (NASDAQ:IMRX) announced its quarterly earnings results on Thursday. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.16), Zacks reports.

Immuneering Stock Performance

Shares of IMRX opened at $1.80 on Friday. The stock has a 50-day moving average of $1.79 and a two-hundred day moving average of $1.99. Immuneering has a one year low of $1.00 and a one year high of $3.83. The stock has a market cap of $55.89 million, a P/E ratio of -0.91 and a beta of -0.32.

Analysts Set New Price Targets

IMRX has been the subject of a number of recent analyst reports. Chardan Capital reissued a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a research report on Wednesday, January 8th. Morgan Stanley cut Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of Immuneering in a research report on Friday.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.